RP-HPLC method development and validation for the simultaneous determination of lamivudine, abacavir and dolutegravir in pharmaceutical dosage forms

Authors

  • Rajkumar Prava A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India.
  • Ganapathy Seru A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India.
  • Vamsi Krishna Pujala KL University, Green Fields, Vaddeswaram, Guntur, Andhra Pradesh, India.
  • Surendra Babu Lagu A.U College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India.

Keywords:

Lamivudine, Abacavir, Dolutegravir, RP-HPLC, HIV

Abstract

Abacavir is an antiretroviral drug used to treat HIV/AIDS. Lamivudine (2′,3′-dideoxy-3′-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. A combination product of the above three drugs is being marketed under the brand name of Triumeq in India. In the present study focus is laid on this triple combination drug, The retention times of Lamivudine, Abacavir and Dolutegravir were found to be 2.2 min, 2.9 min & 7.4 min respectively. Regression coefficient r2 value was 0.999 for Lamivudine, Abacavir and Dolutegravir and the response was linear. The percentage mean recovery of Lamivudine, Abacavir and Dolutegravir were found to be 100.04, 99.73 and 100.29% respectively. %RSD values of repeatability and intermediate precision were ≤2 and the method is precise. The solution stability studies of method indicate that the Lamivudine, Abacavir and Dolutegravir drugs were stable up to 24 hours. Hence, the developed method can be successfully employed for routine quality control of Lamivudine, Abacavir and Dolutegravir in drug testing laboratories and pharmaceutical industries.

Downloads

Published

2017-04-27

How to Cite

Rajkumar Prava, Ganapathy Seru, Vamsi Krishna Pujala, & Surendra Babu Lagu. (2017). RP-HPLC method development and validation for the simultaneous determination of lamivudine, abacavir and dolutegravir in pharmaceutical dosage forms. World Journal of Pharmaceutical Sciences, 5(5), 168–181. Retrieved from https://wjpsonline.com/index.php/wjps/article/view/rp-hplc-development-lamivudine-abacavir-dolutegravir

Issue

Section

Research Article

Most read articles by the same author(s)